Vertex Pharmaceuticals, Inc.

+2.36 (+0.88%)
4:48:04 PM EDT: $271.64 +0.80 (+0.30%)
Regulatory, Earnings Announcements

Vertex Announces Results From Two Phase 2 Proof-Of-Concept Studies Of VX-548 For Pain Treatment

Published: 03/31/2022 12:19 GMT
Vertex Pharmaceuticals, Inc. (VRTX) - Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-concept Studies of Vx-548 for the Treatment of Acute Pain.
Vertex Pharmaceuticals Inc- Vx-548 Was Generally Well Tolerated.
Vertex Pharmaceuticals Inc- Plans to Advance Vx-548 Into Pivotal Development in Acute Pain in H2 2022.
Vertex Pharmaceuticals- Treatment With Nav1.8 Inhibitor Vx-548 Met Primary Endpoint in Both Phase 2 Proof-of-concept Acute Pain Studies Following Abdominoplasty Or Bunionectomy Surgery.
Revenue is expected to be $2.13 Billion
Adjusted EPS is expected to be $3.57

Next Quarter Revenue Guidance is expected to be $2.17 Billion
Next Quarter EPS Guidance is expected to be $3.64

More details on our Analysts Page.